Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
Sarah Cook, Vanessa Samuel, Daniel E. Meyers, et al.
JAMA Network Open (2024) Vol. 7, Iss. 1, pp. e2352302-e2352302
Open Access | Times Cited: 49
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
Jingting Wang, Yan Ma, Haishan Lin, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 25
Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
Li Lin, Yu Liu, Chen Chen, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 25
Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Wei Zhang, Yifei Tan, Yuquan Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
Timothy Rajakumar, Rastislav Horos, Julia Jehn, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 34
Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
Yiran Rong, John P. Bentley, Kaustuv Bhattacharya, et al.
Cancer Medicine (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
A Review of Immunotherapy in Non-Small-Cell Lung Cancer
Mariana Pilon Capella, Steph A. Pang, Marcos Aurélio Fonseca Magalhães, et al.
Current Oncology (2024) Vol. 31, Iss. 6, pp. 3495-3512
Open Access | Times Cited: 5
Distinct immune-effector and metabolic profile of CD8+T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors
Karolina Benesova, Franziska V. Kraus, Rui A. Carvalho, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1730-1741
Open Access | Times Cited: 20
Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study
Miriam Blasi, Jonas Kuon, Rajiv Shah, et al.
Clinical Lung Cancer (2023) Vol. 24, Iss. 7, pp. e282-e290
Closed Access | Times Cited: 12
Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
Shixin Ma, He Nie, Chaoyu Wei, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Yuxiang Liang, Haidi Xu, Futao Liu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Impact of IRAES on the outcomes of pembrolizumab therapy in patients with MUC: A comprehensive analysis of severity and the type and number of affected organs
Ichiro Yonese, Yosuke Yasuda, Kosuke Takemura, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Closed Access
Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer
Yue Hu, Shixun Li, He Xiao, et al.
Cancer Medicine (2023) Vol. 12, Iss. 11, pp. 12234-12252
Open Access | Times Cited: 10
Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
Simona Coniac, Mariana Cristina Costache Outas, Edvina-Elena Pirvu, et al.
Diagnostics (2023) Vol. 13, Iss. 10, pp. 1788-1788
Open Access | Times Cited: 10
Immune-checkpoint Inhibitors in Anti-cancer Armamentarium: a Double-edged Sword in Risk of Developing Autoimmunity and Immune-related Adverse Effects

Frontiers research topics (2025)
Closed Access
Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Xinyu Zhang, Bei Zhang, Danfei Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer
George Raynes, Mark Stares, Samantha Low, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5502-5502
Open Access | Times Cited: 9
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
Michael R. Sayer, Isa Mambetsariev, Kun‐Han Lu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Clinical characteristics and prognostic implications of immune-related hepatitis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study
Manyi Xu, Lan Xu, Hao Yue, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 3, pp. 1900-1910
Open Access | Times Cited: 3
Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study
Kang Liu, Zhongke Qin, Yifei Ge, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 8, pp. 5061-5070
Closed Access | Times Cited: 12
Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review
Jinxiong Xia, Yingmei Wen, Mengxia Xiao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis
Soo Young Hwang, Pinghsin Hsieh, Wei Zhang
Hepatology Communications (2024) Vol. 8, Iss. 10
Open Access | Times Cited: 2
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
Hannah Schindler, Fabienne Lusky, Lea Daniello, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 4, pp. 1659-1666
Closed Access | Times Cited: 11
A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
Wei Liu, Tiantian Zhang, Qian Zhang, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top